For their study, Johns Hopkins researchers compared the costs for four commonly prescribed IV medications — chlorothiazide, voriconazole, levetiracetam and pantoprazole — to their oral equivalents. The researchers concluded Johns Hopkins Hospital could safely reap savings of more than $1.1 million in the Department of Medicine alone (not including surgical patients) by swapping out the IV medications for oral alternatives.
Researchers also concluded a large-scale switch to oral medications has the potential to reduce the need for puncturing veins to insert intravenous tubes or medications directly, which is associated with a higher risk of hospital-acquired bloodstream infections.
The researchers noted that not all patients are able to switch from the IV form to the oral form of a drug.
Related Articles on Cost Savings:
Survey: 69% of Healthcare Leaders Indicate Capital Budgets Are Flat or Increased
Report: Decision-Support, Prior Authorization for Imaging Unlikely to Save Costs
Union at Jackson Health System Agrees to $36M in Labor Cuts
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
